Development of Plasmodium falciparum Protease Inhibitors in the Past Decade (2002-2012)
authors Perez, B; Teixeira, C; Gomes, JRB; Gomes, P
nationality International
journal CURRENT MEDICINAL CHEMISTRY
author keywords Plasmodium falciparum; hemoglobin catabolism; plasmepsin; falcipain; falcilysin; aminopeptidase; proteases; antimalarial
keywords POTENTIAL ANTIMALARIAL AGENTS; EXCESS HEMOGLOBIN DIGESTION; M17 LEUCINE AMINOPEPTIDASE; PLASMEPSIN-II INHIBITORS; PEPTIDYL VINYL SULFONES; CYSTEINE PROTEASE; IN-VITRO; MALARIA PARASITES; ACTIVE-SITE; FARNESYLTRANSFERASE INHIBITORS
abstract New drug targets for the development of antimalarial drugs have emerged after the unveiling of the Plasmodium falciparum genome in 2002. Potential antimalarial drug targets can be broadly classified into three categories according to their function in the parasite's life cycle: (i) biosynthesis, (ii) membrane transport and signaling, and (iii) hemoglobin catabolism. The latter plays a key role, as inhibition of hemoglobin degradation impairs maturation of blood-stage malaria parasites, ultimately leading to remission or even cure of the most severe stage of the infection. Intraerythrocytic Plasmodia parasites have limited capacity to biosynthesize amino acids which are vital for their growth. Therefore, the parasites obtain those essential amino acids via degradation of host cell hemoglobin, making this a crucial process for parasite survival. Several plasmodial proteases are involved in hemoglobin catabolism, among which plasmepsins and falcipains are well-known examples. Hence, development of P. falciparum protease inhibitors is a promising approach to antimalarial chemotherapy, as highlighted by the present review which is focused on the Medicinal Chemistry research effort recorded in the past decade in this particular field.
publisher BENTHAM SCIENCE PUBL LTD
issn 0929-8673
year published 2013
volume 20
issue 25
beginning page 3049
ending page 3068
web of science category Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology & Pharmacy
subject category Biochemistry & Molecular Biology; Pharmacology & Pharmacy
unique article identifier WOS:000321557300003
  ciceco authors
  impact metrics
journal analysis (jcr 2017):
journal impact factor 3.469
5 year journal impact factor 3.519
category normalized journal impact factor percentile 71.089
altmetrics (social interaction):



 


Sponsors

1suponsers_list_ciceco.jpg